Who are r-FSH plus HP-hMG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo, gonadotropins in step-up regimen, recombinant gonadotropins, ovarian stimulation, High dose gonadotropins, Ovarian Stimulation with CC+rFSH, FSH+LH.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-fsh-plus-hp-hmg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

r-FSH plus HP-hMG — Competitive Intelligence Brief

r-FSH plus HP-hMG (r-FSH plus HP-hMG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin combination. Area: Reproductive Medicine / Fertility.

marketed Gonadotropin combination FSH receptor, LH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

r-FSH plus HP-hMG (r-FSH plus HP-hMG) — Instituto Valenciano de Infertilidad, IVI VALENCIA. A combination of recombinant follicle-stimulating hormone (r-FSH) and highly purified human menopausal gonadotropin (HP-hMG) that stimulates ovarian follicle development and hormone production for assisted reproductive technology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
r-FSH plus HP-hMG TARGET	r-FSH plus HP-hMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin combination	FSH receptor, LH receptor
Placebo, gonadotropins in step-up regimen	Placebo, gonadotropins in step-up regimen	University of Modena and Reggio Emilia	marketed	Gonadotropin	FSH receptor, LH receptor
recombinant gonadotropins	recombinant gonadotropins	Sheba Medical Center	marketed	Gonadotropin	FSH receptor, LH receptor
ovarian stimulation	ovarian stimulation	Ain Shams Maternity Hospital	marketed	Gonadotropin	FSH receptor, LH receptor
High dose gonadotropins	High dose gonadotropins	Weill Medical College of Cornell University	marketed	Gonadotropin	FSH receptor, LH receptor
Ovarian Stimulation with CC+rFSH	Ovarian Stimulation with CC+rFSH	Fundación Santiago Dexeus Font	marketed	Gonadotropin combination therapy	FSH receptor (FSHR); estrogen receptor (ER) antagonism
FSH+LH	FSH+LH	Instituto Valenciano de Infertilidad, IVI VALENCIA	phase 3	Gonadotropin combination	FSH receptor (FSHR) and LH receptor (LHCGR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gonadotropin combination class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). r-FSH plus HP-hMG — Competitive Intelligence Brief. https://druglandscape.com/ci/r-fsh-plus-hp-hmg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab